Contact number:
400 007 5658
-
R&D
With the R&D and manufacture of controlled-release drug products as the core business, Anbison focuses on development of high-end controlled-release dosage forms and finished dosage forms that are inherently difficult to manufacture. Meanwhile, we are actively expanding to 505b(2) drugs and complex long-acting injectables.
To learn more, please slide the window left and right
| Product Name | Status | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Atorvastatin Calcium Tablets | Submitted to NMPA | ||||
| Bupropion Hydrochloride Extended-Release Tablets | Submitted to NMPA | ||||
| Montelukast Sodium Granules | Submitted to NMPA | ||||
| Carbamazepine Extended-Release Tablets | Submitted to FDA and NMPA | ||||
| Felodipine Extended-Release Tablets | Submitted to NMPA and UK | ||||
| Glipizide Extended-Release Tablets | Clinical trial | ||||
| Esomeprazole Magnesium Granules | Clinical trial | ||||
| Rabeprazole Delayed-Release Tablets | Clinical trial | ||||
| ABS1001 | Clinical trial | ||||
| ABS1002 | Clinical trial | ||||
| ABS1003 | Clinical trial | ||||
| ABS1004 | Clinical trial |